Nothing Special   »   [go: up one dir, main page]

ATE208819T1 - Löslicher t-zell rezeptor - Google Patents

Löslicher t-zell rezeptor

Info

Publication number
ATE208819T1
ATE208819T1 AT99922360T AT99922360T ATE208819T1 AT E208819 T1 ATE208819 T1 AT E208819T1 AT 99922360 T AT99922360 T AT 99922360T AT 99922360 T AT99922360 T AT 99922360T AT E208819 T1 ATE208819 T1 AT E208819T1
Authority
AT
Austria
Prior art keywords
cell receptor
mhc
soluble
cell
multivalent
Prior art date
Application number
AT99922360T
Other languages
English (en)
Inventor
Bent Karsten Jakobsen
John Irving Bell
George Fu Gao
Benjamin Ernest Willcox
Jonathan Michael Boulter
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810759.2A external-priority patent/GB9810759D0/en
Priority claimed from GBGB9821129.5A external-priority patent/GB9821129D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Application granted granted Critical
Publication of ATE208819T1 publication Critical patent/ATE208819T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99922360T 1998-05-19 1999-05-19 Löslicher t-zell rezeptor ATE208819T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9810759.2A GB9810759D0 (en) 1998-05-19 1998-05-19 Soluble t cell receptor
GBGB9821129.5A GB9821129D0 (en) 1998-09-29 1998-09-29 Multimeric T cell receptor
PCT/GB1999/001588 WO1999060120A2 (en) 1998-05-19 1999-05-19 Soluble t cell receptor

Publications (1)

Publication Number Publication Date
ATE208819T1 true ATE208819T1 (de) 2001-11-15

Family

ID=26313710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922360T ATE208819T1 (de) 1998-05-19 1999-05-19 Löslicher t-zell rezeptor

Country Status (28)

Country Link
US (4) US20020119149A1 (de)
EP (2) EP1080193A2 (de)
JP (2) JP2002515244A (de)
KR (2) KR20010085250A (de)
CN (2) CN1308674A (de)
AT (1) ATE208819T1 (de)
AU (2) AU746164B2 (de)
BG (1) BG105053A (de)
BR (1) BR9910253A (de)
CA (2) CA2328144A1 (de)
DE (1) DE69900468T2 (de)
DK (1) DK1066380T3 (de)
EA (1) EA200001216A1 (de)
EE (1) EE200000697A (de)
ES (1) ES2168866T3 (de)
HK (1) HK1035739A1 (de)
HR (1) HRP20000790A2 (de)
HU (1) HUP0103614A2 (de)
ID (1) ID28040A (de)
IL (2) IL139344A0 (de)
IS (1) IS5697A (de)
NO (2) NO20005812L (de)
NZ (2) NZ507887A (de)
PL (1) PL364734A1 (de)
PT (1) PT1066380E (de)
SK (1) SK17332000A3 (de)
TR (1) TR200003391T2 (de)
WO (2) WO1999060120A2 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168866T3 (es) * 1998-05-19 2002-06-16 Avidex Ltd Receptor de celulas t soluble.
EP1118661A1 (de) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T-Zellrezeptor-Bibliotheken
CA2410642A1 (en) * 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
AU2002361559A1 (en) 2001-09-24 2003-04-28 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1482987B1 (de) * 2002-03-01 2014-08-13 Bracco Suisse SA Multivalente konstrukte für therapeutische und diagnostische anwendungen
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1575994B1 (de) 2002-09-27 2013-01-09 Ludwig Institute for Cancer Research Ltd. Mage-c2-antigene peptide und deren verwendungen
EP1549748B1 (de) * 2002-10-09 2014-10-01 Immunocore Ltd. Einkettige rekombinante t-zell rezeptoren
JP4975324B2 (ja) * 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
JP2006523437A (ja) * 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
CA2530184C (en) 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
CN1901839A (zh) 2003-11-10 2007-01-24 阿尔特生物科学公司 可溶性tcr分子及其用途
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
WO2005062959A2 (en) * 2003-12-22 2005-07-14 The University Of Tennessee Research Foundation Isolated t lymphocyte receptors specific for human autoantigens complexed with human mhc molecules and methods of making and using same
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
GB0427585D0 (en) * 2004-12-16 2005-01-19 Avidex Ltd Assay
CN105461802A (zh) * 2005-04-01 2016-04-06 英美偌科有限公司 高亲和力hiv t细胞受体
AU2006245512B2 (en) 2005-05-13 2011-12-22 Oxford Biomedica (Uk) Limited Peptide
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
EP2463307A1 (de) * 2005-08-31 2012-06-13 CBIO Limited Modifiziertes Chaperonin 10
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
KR20090015034A (ko) * 2006-04-05 2009-02-11 더 제너럴 하스피톨 코포레이션 가용성 바이러스-특이적 ｔ-세포 수용체의 조성물
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2008102469A1 (ja) * 2007-02-23 2008-08-28 Kwansei Gakuin Educational Foundation 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
AU2013206501B2 (en) * 2007-03-05 2016-05-19 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
CA2679045A1 (en) 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
KR100877480B1 (ko) * 2007-06-08 2009-01-07 왕성호 숫자 기억 게임 방법
EP3023436A1 (de) * 2007-07-03 2016-05-25 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP2445924B2 (de) 2009-06-25 2023-12-13 Amgen Inc. Vefahren zur aufreinigung von proteinen aus prokaryotischen zellen
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
EP2694709B1 (de) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptidkonstrukte und testsysteme dafür
CN105968191A (zh) * 2011-06-28 2016-09-28 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
PT2831109T (pt) 2012-03-28 2018-02-07 Gadeta B V Resumo
AU2013295652B2 (en) 2012-07-27 2018-02-08 The Board Of Trustees Of The University Of Illinois Engineering T-cell receptors
CA2883569A1 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (de) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target-peptide für therapie und diagnostik von kolorektalkarzinomen
EP2931312A4 (de) 2012-12-13 2016-10-19 Univ Virginia Patent Found Target-peptide für therapie und diagnostik von ovarialkarzinom
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
EP3736573A1 (de) * 2013-03-15 2020-11-11 Prognosys Biosciences, Inc. Verfahren zum nachweis von peptid/mhc/tcr-bindung
KR20160085345A (ko) 2013-11-22 2016-07-15 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
EP3083674B1 (de) 2013-12-19 2018-10-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Grippenspezifischer t-zellenrezeptor und seine verwendung bei der erkennung, prävention und/oder behandlung von grippe
JP2017511151A (ja) 2014-03-14 2017-04-20 イムノコア リミテッド Ｔｃｒライブラリ
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
GB201409558D0 (en) * 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
JP2018532386A (ja) 2015-09-09 2018-11-08 イミューン デザイン コーポレイション Ｎｙ−ｅｓｏ−１特異的ｔｃｒおよびそれらの使用方法
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
EP3399985B1 (de) * 2016-01-06 2022-02-23 Health Research, Inc. Zusammensetzungen und bibliotheken mit rekombinanten t-zellrezeptoren und verfahren zur verwendung rekombinanter t-zellrezeptoren
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
AU2017261380A1 (en) 2016-05-06 2018-11-22 Editas Medicine, Inc. Genetically engineered cells and methods of making the same
MX2018014863A (es) 2016-06-02 2019-09-11 Immunocore Ltd Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
CA3027124A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP2019536437A (ja) 2016-10-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
MA50839A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
AU2017355544A1 (en) 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
AU2017368332A1 (en) 2016-12-03 2019-06-13 Juno Therapeutics, Inc. Methods for modulation of CAR-T cells
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
RU2019120398A (ru) 2016-12-03 2021-01-12 Джуно Терапьютикс, Инк. Способы определения дозировки cart-клеток
MX2019006438A (es) 2016-12-05 2019-11-28 Juno Therapeutics Inc Produccion de celulas modificadas para terapia de celulas adoptivas.
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
AU2018224856A1 (en) 2017-02-27 2019-08-29 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
EP3589295B1 (de) 2017-02-28 2024-09-11 Endocyte, Inc. Zusammensetzungen und verfahren für car-t-zelltherapie
CA3056393A1 (en) 2017-03-14 2018-09-20 Juno Therapeutics, Inc. Methods for cryogenic storage
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
EP3610261A1 (de) 2017-04-14 2020-02-19 Juno Therapeutics, Inc. Verfahren zur beurteilung der zelloberflächenglykosylierung
EP3618842B1 (de) 2017-05-01 2023-10-18 Juno Therapeutics, Inc. Kombination einer zelltherapie und einer immunmodulatorischen verbindung
CN107216371B (zh) * 2017-05-27 2020-09-18 浙江师范大学 一种成人t细胞白血病的特异性靶向多肽及其应用
MA48781A (fr) 2017-06-02 2020-04-08 Juno Therapeutics Inc Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
CN111246861A (zh) 2017-07-29 2020-06-05 朱诺治疗学股份有限公司 扩增表达重组受体的细胞的试剂
CN111246862A (zh) 2017-08-09 2020-06-05 朱诺治疗学股份有限公司 产生基因工程化细胞组合物的方法和相关组合物
MX2020001491A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos y composiciones para preparar celulas geneticamente modificadas.
EP3676403A1 (de) 2017-09-01 2020-07-08 Juno Therapeutics, Inc. Genexpression und beurteilung des risikos der entwicklung von toxizität nach einer zelltherapie
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
KR20200104284A (ko) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
US20230061455A1 (en) 2017-11-01 2023-03-02 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
EP3704230B1 (de) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Verfahren zur herstellung von therapeutischen zusammensetzungen von gentechnisch veränderten zellen
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP2021502077A (ja) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
CN111886012A (zh) 2017-11-06 2020-11-03 朱诺治疗学股份有限公司 细胞疗法与γ分泌酶抑制剂的组合
GB201719169D0 (en) 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
JP2021505168A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
CN112203680A (zh) 2017-12-08 2021-01-08 朱诺治疗学股份有限公司 用于细胞疗法的表型标记和相关方法
JP7417542B2 (ja) 2018-01-22 2024-01-18 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Ｃａｒ ｔ細胞の使用方法
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
US20210069246A1 (en) 2018-01-31 2021-03-11 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
SG11202009284TA (en) 2018-04-05 2020-10-29 Juno Therapeutics Inc T cell receptors and engineered cells expressing same
US20210015869A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
BR112020020245A2 (pt) 2018-04-05 2021-04-06 Editas Medicine, Inc. Métodos de produzir células expressando um receptor recombinante e composições relacionadas
US20220275043A1 (en) * 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
AU2019316647A1 (en) 2018-08-09 2021-02-25 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
KR20210081341A (ko) 2018-09-11 2021-07-01 주노 쎄러퓨티크스 인코퍼레이티드 조작된 세포 조성물의 질량 분석기 분석을 위한 방법
US20210380661A1 (en) * 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
JP7569313B2 (ja) 2018-10-23 2024-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
EP3874024A1 (de) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Verfahren zur selektion und stimulation von zellen und vorrichtung dafür
CA3117841A1 (en) * 2018-11-02 2020-05-07 University Of Washington Orthogonal protein heterodimers
ES2968737T3 (es) 2018-11-06 2024-05-13 Juno Therapeutics Inc Proceso para producir células T manipuladas genéticamente
AU2019377854A1 (en) 2018-11-08 2021-05-27 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
WO2020113188A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
US20220088070A1 (en) 2018-11-30 2022-03-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
BR112021021075A2 (pt) 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
EA202193121A1 (ru) 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. Лечение рака
WO2020247832A1 (en) 2019-06-07 2020-12-10 Juno Therapeutics, Inc. Automated t cell culture
JP2022537700A (ja) 2019-06-12 2022-08-29 ジュノー セラピューティクス インコーポレイテッド 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
KR20220132527A (ko) 2019-12-06 2022-09-30 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법
EP4093753A1 (de) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Bevorzugt exprimierte antigene in melanomen (prame) t-zell-rezeptoren und verfahren zur verwendung davon
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
US20210403528A1 (en) * 2020-05-21 2021-12-30 University College Cardiff Consultants Ltd. Novel T-Cell Receptor and Ligand
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
AU2021364387A1 (en) 2020-10-23 2023-06-15 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
EP4301755A1 (de) 2021-03-03 2024-01-10 Juno Therapeutics, Inc. Kombination aus t-zelltherapie und dgk-hemmer
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
EP4313127A1 (de) 2021-03-29 2024-02-07 Juno Therapeutics, Inc. Verfahren zur dosierung und behandlung mit einer kombination aus einer checkpoint-inhibitor-therapie und einer car-t-zelltherapie
EP4334341A2 (de) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Verfahren zur stimulierung und transduktion von t-zellen
WO2023283446A1 (en) * 2021-07-09 2023-01-12 The Johns Hopkins University Method for surface expression of membrane proteins that have a cytoplasmic c-terminal tail
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
US20240148867A1 (en) 2022-10-31 2024-05-09 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4040669A1 (de) * 1990-12-19 1992-06-25 Behringwerke Ag Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik
US5328985A (en) * 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
AR246435A1 (es) * 1992-08-20 1994-08-31 Moreno Saul Jeringa descartable para uso con cubreagujas
WO1996021028A2 (en) * 1995-01-03 1996-07-11 Procept, Inc. Soluble heterodimeric t cell receptors and their antibodies
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6015884A (en) * 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
ES2221065T3 (es) * 1996-08-16 2004-12-16 The President And Fellows Of Harvard College Proteinas de fusion de clase ii del mhc, solubles, monovalentes o polivalentes, y sus usos.
ES2168866T3 (es) * 1998-05-19 2002-06-16 Avidex Ltd Receptor de celulas t soluble.

Also Published As

Publication number Publication date
KR100530309B1 (ko) 2005-11-22
EE200000697A (et) 2002-06-17
AU758949B2 (en) 2003-04-03
NO20005812D0 (no) 2000-11-17
KR20010085250A (ko) 2001-09-07
CA2328144A1 (en) 1999-11-25
AU3945699A (en) 1999-12-06
BR9910253A (pt) 2002-09-17
JP2002515244A (ja) 2002-05-28
IL139345A0 (en) 2001-11-25
PL364734A1 (en) 2004-12-13
ES2168866T3 (es) 2002-06-16
KR20010043675A (ko) 2001-05-25
NO20005812L (no) 2001-01-19
EP1066380A2 (de) 2001-01-10
IL139344A0 (en) 2001-11-25
AU3945999A (en) 1999-12-06
CN1306572A (zh) 2001-08-01
AU746164B2 (en) 2002-04-18
ID28040A (id) 2001-05-03
EA200001216A1 (ru) 2001-06-25
TR200003391T2 (tr) 2001-02-21
NO20005811D0 (no) 2000-11-17
IS5697A (is) 2000-10-31
DE69900468D1 (de) 2001-12-20
EP1080193A2 (de) 2001-03-07
US20020142389A1 (en) 2002-10-03
WO1999060120A3 (en) 2000-02-03
HUP0103614A2 (hu) 2002-01-28
WO1999060119A3 (en) 2000-02-03
NZ507887A (en) 2002-12-20
EP1066380B1 (de) 2001-11-14
HRP20000790A2 (en) 2001-06-30
HK1035739A1 (en) 2001-12-07
JP2002515243A (ja) 2002-05-28
DE69900468T2 (de) 2002-07-18
US20060093613A1 (en) 2006-05-04
CN1308674A (zh) 2001-08-15
CA2327314A1 (en) 1999-11-25
DK1066380T3 (da) 2002-01-28
WO1999060119A2 (en) 1999-11-25
NZ507886A (en) 2003-05-30
PT1066380E (pt) 2002-05-31
US20020119149A1 (en) 2002-08-29
BG105053A (bg) 2001-09-28
SK17332000A3 (sk) 2001-06-11
NO20005811L (no) 2001-01-19
US20060155115A1 (en) 2006-07-13
WO1999060120A2 (en) 1999-11-25
CN1249229C (zh) 2006-04-05

Similar Documents

Publication Publication Date Title
ATE208819T1 (de) Löslicher t-zell rezeptor
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
NO20031179L (no) Chemokin-reseptorbindende heterocykliske forbindelser
DE69814878D1 (de) 1-amino-alkylcyclohexane als nmda-rezeptor-antagonisten
DE69434908D1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
ATE258963T1 (de) Farbstoff-markierte imidazochinolinverbindungen
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
MA24794A1 (fr) D-methadone, un analgesique nonopioique
CO5460266A1 (es) Novedosos analogos de la somatostatina
TR200102041T2 (tr) Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
SE9702794D0 (sv) New compounds
GB9811221D0 (en) Bacterial-pheromones and uses therefor
DK1224222T3 (da) Chemokinreceptor
GB0008321D0 (en) Biological material and uses thereof
DK266289D0 (da) Alfa-adrenerge receptorantagonister, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse antagonister
WO2001023563A3 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
BR0002142A (pt) Inibidores de quinase myti
ATE360426T1 (de) Verwendung von agonisten der corticosteroidrezeptoren und einer suchtdroge zur suchtbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066380

Country of ref document: EP

REN Ceased due to non-payment of the annual fee